Erectile Dysfunction Protocol
Primary Stack
Core supplements with strongest evidenceConverted to arginine, increasing nitric oxide production and improving blood flow to erectile tissue
Supporting Studies (1)
Ginsenosides enhance nitric oxide release and relax smooth muscle in erectile tissue
Supporting Stack
Additional supplements for enhanced resultsImproves energy metabolism in penile tissue; propionyl-L-carnitine may enhance PDE5 inhibitor response
Supporting Studies (1)
Adaptogen that improves sexual desire and may enhance erectile function through non-hormonal mechanisms
Supporting Studies (1)
May support testosterone levels and enhance libido; traditional use for sexual dysfunction
Supporting Studies (1)
Pine bark extract that enhances endothelial nitric oxide production; often combined with L-arginine
May improve erectile function and sexual satisfaction; especially studied in SSRI-induced dysfunction
Supporting Studies (1)
How This Protocol Works
Simple Explanation
Erectile dysfunction (ED) is the inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It affects about 50% of men over 40 to some degree and becomes more common with age. ED is primarily a vascular condition—erections depend on adequate blood flow. Nitric oxide (NO) is the key molecule that relaxes blood vessels and allows blood to fill the erectile tissue. ED can also be an early warning sign of cardiovascular disease.
IMPORTANT: ED can signal underlying cardiovascular disease, diabetes, or hormonal problems. See a healthcare provider for evaluation. PDE5 inhibitors (Viagra, Cialis) remain the most effective treatment for most men.
Expected timeline: L-citrulline/Pycnogenol: days to weeks. Ginseng: 2-4 weeks. Maca/Tribulus: 4-8 weeks. Lifestyle factors (exercise, weight loss, not smoking) are also important.
Clinical Perspective
Erectile dysfunction involves failure of the penile erection mechanism. The physiological process requires: (1) sexual stimulation releasing NO from nerve terminals and endothelium, (2) NO activating guanylate cyclase → cGMP → smooth muscle relaxation, (3) increased arterial inflow and venous occlusion. ED is ~80% vascular in etiology; risk factors mirror cardiovascular disease. PDE5 inhibitors are first-line treatment with 60-80% efficacy.
CRITICAL: ED is an independent predictor of cardiovascular events. Evaluate for underlying conditions: cardiovascular disease, diabetes, hypogonadism, medication effects. Supplements may be adjunctive or for mild cases not requiring pharmacotherapy.
Biomarker targets: IIEF-5 score, nocturnal penile tumescence (if diagnostic uncertainty), testosterone (total, free), prolactin, fasting glucose/HbA1c, lipid panel, PSA if indicated, cardiovascular risk assessment.
Protocol notes: Lifestyle modifications critical: stop smoking (smoking causes ED), exercise regularly (improves endothelial function), lose excess weight (obesity impairs testosterone and blood flow), limit alcohol. PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) remain most effective—try different agents if one fails. Vacuum erection devices, intracavernosal injection (alprostadil), and penile prostheses for refractory cases. Low testosterone: evaluate for TRT if indicated. Psychological factors: performance anxiety, depression—consider sex therapy. Avoid unregulated 'male enhancement' products—many contain hidden PDE5 inhibitors at dangerous doses. Pelvic floor exercises may help. Address relationship issues. Medications that cause ED: beta-blockers, thiazides, antidepressants, antiandrogens.